Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders

Herbert M. Lachman, Demitri F. Papolos, Takuya Saito, Yue Min Yu, Carol L. Szumlanski, Richard M Weinshilboum

Research output: Contribution to journalArticle

1426 Citations (Scopus)

Abstract

Catechol-O-methyltransferase (COMT) inactivates catecholamines and catechol drugs such as L-DOPA. A common genetic polymorphism in humans is associated with a three-to-fourfold variation in COMT enzyme activity and is also associated with individual variation in COMT thermal instability. We now show that this is due to G→A transition at codon 158 of the COMT gene that results in a valine to methionine substitution. The two alleles can be identified with a PCR-based restriction fragment length polymorphism analysis using the restriction enzyme NIa III. The identification of a genetic marker associated with significant alterations in enzyme activity will facilitate the analysis of a possible role for the COMT gene in neuropsychiatric conditions in which abnormalities in catecholamine neurotransmission are believed to occur, including mood disorders, schizophrenia, obsessive compulsive disorder, alcohol and substance abuse, and attention deficit hyperactivity disorder. In addition, this polymorphism may have pharmacogenetic significance in that it will help make it possible to identify patients who display altered metabolism of catechol drugs.

Original languageEnglish (US)
Pages (from-to)243-250
Number of pages8
JournalPharmacogenetics
Volume6
Issue number3
DOIs
StatePublished - 1996

Fingerprint

Catechol O-Methyltransferase
Pharmacogenetics
Catecholamines
Restriction Mapping
Obsessive-Compulsive Disorder
Valine
Genetic Polymorphisms
Enzymes
Attention Deficit Disorder with Hyperactivity
Mood Disorders
Genetic Markers
Codon
Synaptic Transmission
Restriction Fragment Length Polymorphisms
Pharmaceutical Preparations
Methionine
Alcoholism
Genes
Substance-Related Disorders
Schizophrenia

Keywords

  • Catechol
  • Methyltransferase
  • O-methyltransferase
  • Parkinson's disease
  • Velo cardio facial syndrome

ASJC Scopus subject areas

  • Genetics
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Human catechol-O-methyltransferase pharmacogenetics : Description of a functional polymorphism and its potential application to neuropsychiatric disorders. / Lachman, Herbert M.; Papolos, Demitri F.; Saito, Takuya; Yu, Yue Min; Szumlanski, Carol L.; Weinshilboum, Richard M.

In: Pharmacogenetics, Vol. 6, No. 3, 1996, p. 243-250.

Research output: Contribution to journalArticle

Lachman, Herbert M. ; Papolos, Demitri F. ; Saito, Takuya ; Yu, Yue Min ; Szumlanski, Carol L. ; Weinshilboum, Richard M. / Human catechol-O-methyltransferase pharmacogenetics : Description of a functional polymorphism and its potential application to neuropsychiatric disorders. In: Pharmacogenetics. 1996 ; Vol. 6, No. 3. pp. 243-250.
@article{85e26bf5e8e54c19bd6d5379c7725995,
title = "Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders",
abstract = "Catechol-O-methyltransferase (COMT) inactivates catecholamines and catechol drugs such as L-DOPA. A common genetic polymorphism in humans is associated with a three-to-fourfold variation in COMT enzyme activity and is also associated with individual variation in COMT thermal instability. We now show that this is due to G→A transition at codon 158 of the COMT gene that results in a valine to methionine substitution. The two alleles can be identified with a PCR-based restriction fragment length polymorphism analysis using the restriction enzyme NIa III. The identification of a genetic marker associated with significant alterations in enzyme activity will facilitate the analysis of a possible role for the COMT gene in neuropsychiatric conditions in which abnormalities in catecholamine neurotransmission are believed to occur, including mood disorders, schizophrenia, obsessive compulsive disorder, alcohol and substance abuse, and attention deficit hyperactivity disorder. In addition, this polymorphism may have pharmacogenetic significance in that it will help make it possible to identify patients who display altered metabolism of catechol drugs.",
keywords = "Catechol, Methyltransferase, O-methyltransferase, Parkinson's disease, Velo cardio facial syndrome",
author = "Lachman, {Herbert M.} and Papolos, {Demitri F.} and Takuya Saito and Yu, {Yue Min} and Szumlanski, {Carol L.} and Weinshilboum, {Richard M}",
year = "1996",
doi = "10.1097/00008571-199606000-00007",
language = "English (US)",
volume = "6",
pages = "243--250",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Human catechol-O-methyltransferase pharmacogenetics

T2 - Description of a functional polymorphism and its potential application to neuropsychiatric disorders

AU - Lachman, Herbert M.

AU - Papolos, Demitri F.

AU - Saito, Takuya

AU - Yu, Yue Min

AU - Szumlanski, Carol L.

AU - Weinshilboum, Richard M

PY - 1996

Y1 - 1996

N2 - Catechol-O-methyltransferase (COMT) inactivates catecholamines and catechol drugs such as L-DOPA. A common genetic polymorphism in humans is associated with a three-to-fourfold variation in COMT enzyme activity and is also associated with individual variation in COMT thermal instability. We now show that this is due to G→A transition at codon 158 of the COMT gene that results in a valine to methionine substitution. The two alleles can be identified with a PCR-based restriction fragment length polymorphism analysis using the restriction enzyme NIa III. The identification of a genetic marker associated with significant alterations in enzyme activity will facilitate the analysis of a possible role for the COMT gene in neuropsychiatric conditions in which abnormalities in catecholamine neurotransmission are believed to occur, including mood disorders, schizophrenia, obsessive compulsive disorder, alcohol and substance abuse, and attention deficit hyperactivity disorder. In addition, this polymorphism may have pharmacogenetic significance in that it will help make it possible to identify patients who display altered metabolism of catechol drugs.

AB - Catechol-O-methyltransferase (COMT) inactivates catecholamines and catechol drugs such as L-DOPA. A common genetic polymorphism in humans is associated with a three-to-fourfold variation in COMT enzyme activity and is also associated with individual variation in COMT thermal instability. We now show that this is due to G→A transition at codon 158 of the COMT gene that results in a valine to methionine substitution. The two alleles can be identified with a PCR-based restriction fragment length polymorphism analysis using the restriction enzyme NIa III. The identification of a genetic marker associated with significant alterations in enzyme activity will facilitate the analysis of a possible role for the COMT gene in neuropsychiatric conditions in which abnormalities in catecholamine neurotransmission are believed to occur, including mood disorders, schizophrenia, obsessive compulsive disorder, alcohol and substance abuse, and attention deficit hyperactivity disorder. In addition, this polymorphism may have pharmacogenetic significance in that it will help make it possible to identify patients who display altered metabolism of catechol drugs.

KW - Catechol

KW - Methyltransferase

KW - O-methyltransferase

KW - Parkinson's disease

KW - Velo cardio facial syndrome

UR - http://www.scopus.com/inward/record.url?scp=0030004521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030004521&partnerID=8YFLogxK

U2 - 10.1097/00008571-199606000-00007

DO - 10.1097/00008571-199606000-00007

M3 - Article

C2 - 8807664

AN - SCOPUS:0030004521

VL - 6

SP - 243

EP - 250

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 3

ER -